FDA Extends Approval To Amgen’s Vectibix

May 23, 2014 11:41 PM

14 0

FDA Extends Approval To Amgen’s Vectibix

From now on, Amgen’s Vectibix drug can be used as a first line therapy for patients who have a genetic cancer mutation that responds well to the drug

The Food and Drug Administration (FDA) extended approval to Amgen, Inc.’s (AMGN) drug, Vectibix, for usage as a first-line therapy drug for patients who tested positive for wild gene tumors, as long as it is used in combination with chemotherapy.

Also read: U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

Read more

To category page